A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors December 14, 2017 Type of Cancer Solid Tumor Sponsor Moderna Protocol Number mRNA-4157-P101 To Learn More Call (201)-510-0950
